line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,40857094.404443,JAGSNPHARM.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.207532,JAGSNPHARM.NS
Normalized EBITDA,2025-03-31 00:00:00,592609000.0,JAGSNPHARM.NS
Total Unusual Items,2025-03-31 00:00:00,196871000.0,JAGSNPHARM.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,196871000.0,JAGSNPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,553611000.0,JAGSNPHARM.NS
Reconciled Depreciation,2025-03-31 00:00:00,81310000.0,JAGSNPHARM.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,964380000.0,JAGSNPHARM.NS
EBITDA,2025-03-31 00:00:00,789480000.0,JAGSNPHARM.NS
EBIT,2025-03-31 00:00:00,708170000.0,JAGSNPHARM.NS
Net Interest Income,2025-03-31 00:00:00,-9580000.0,JAGSNPHARM.NS
Interest Expense,2025-03-31 00:00:00,9580000.0,JAGSNPHARM.NS
Interest Income,2025-03-31 00:00:00,,JAGSNPHARM.NS
Normalized Income,2025-03-31 00:00:00,397597094.404443,JAGSNPHARM.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,553611000.0,JAGSNPHARM.NS
Total Expenses,2025-03-31 00:00:00,2257760000.0,JAGSNPHARM.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,JAGSNPHARM.NS
Diluted Average Shares,2025-03-31 00:00:00,,JAGSNPHARM.NS
Basic Average Shares,2025-03-31 00:00:00,,JAGSNPHARM.NS
Diluted EPS,2025-03-31 00:00:00,,JAGSNPHARM.NS
Basic EPS,2025-03-31 00:00:00,,JAGSNPHARM.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,553611000.0,JAGSNPHARM.NS
Net Income Common Stockholders,2025-03-31 00:00:00,553611000.0,JAGSNPHARM.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,JAGSNPHARM.NS
Net Income,2025-03-31 00:00:00,553611000.0,JAGSNPHARM.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,553610000.0,JAGSNPHARM.NS
Net Income Continuous Operations,2025-03-31 00:00:00,553610000.0,JAGSNPHARM.NS
Tax Provision,2025-03-31 00:00:00,144980000.0,JAGSNPHARM.NS
Pretax Income,2025-03-31 00:00:00,698590000.0,JAGSNPHARM.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,81900000.0,JAGSNPHARM.NS
Special Income Charges,2025-03-31 00:00:00,196871000.0,JAGSNPHARM.NS
Other Special Charges,2025-03-31 00:00:00,,JAGSNPHARM.NS
Write Off,2025-03-31 00:00:00,,JAGSNPHARM.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-9580000.0,JAGSNPHARM.NS
Total Other Finance Cost,2025-03-31 00:00:00,,JAGSNPHARM.NS
Interest Expense Non Operating,2025-03-31 00:00:00,9580000.0,JAGSNPHARM.NS
Interest Income Non Operating,2025-03-31 00:00:00,,JAGSNPHARM.NS
Operating Income,2025-03-31 00:00:00,429400000.0,JAGSNPHARM.NS
Operating Expense,2025-03-31 00:00:00,1293380000.0,JAGSNPHARM.NS
Other Operating Expenses,2025-03-31 00:00:00,502740000.0,JAGSNPHARM.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,81310000.0,JAGSNPHARM.NS
Depreciation Income Statement,2025-03-31 00:00:00,81310000.0,JAGSNPHARM.NS
Selling General And Administration,2025-03-31 00:00:00,,JAGSNPHARM.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,JAGSNPHARM.NS
General And Administrative Expense,2025-03-31 00:00:00,,JAGSNPHARM.NS
Rent And Landing Fees,2025-03-31 00:00:00,,JAGSNPHARM.NS
Gross Profit,2025-03-31 00:00:00,1722780000.0,JAGSNPHARM.NS
Cost Of Revenue,2025-03-31 00:00:00,964380000.0,JAGSNPHARM.NS
Total Revenue,2025-03-31 00:00:00,2687160000.0,JAGSNPHARM.NS
Operating Revenue,2025-03-31 00:00:00,2687160000.0,JAGSNPHARM.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,JAGSNPHARM.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.247949,JAGSNPHARM.NS
Normalized EBITDA,2024-03-31 00:00:00,323460000.0,JAGSNPHARM.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,JAGSNPHARM.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,JAGSNPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Reconciled Depreciation,2024-03-31 00:00:00,16630000.0,JAGSNPHARM.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,799770000.0,JAGSNPHARM.NS
EBITDA,2024-03-31 00:00:00,323460000.0,JAGSNPHARM.NS
EBIT,2024-03-31 00:00:00,306830000.0,JAGSNPHARM.NS
Net Interest Income,2024-03-31 00:00:00,-8140000.0,JAGSNPHARM.NS
Interest Expense,2024-03-31 00:00:00,8140000.0,JAGSNPHARM.NS
Interest Income,2024-03-31 00:00:00,85920000.0,JAGSNPHARM.NS
Normalized Income,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Total Expenses,2024-03-31 00:00:00,1872980000.0,JAGSNPHARM.NS
Rent Expense Supplemental,2024-03-31 00:00:00,9130000.0,JAGSNPHARM.NS
Diluted Average Shares,2024-03-31 00:00:00,66262537.0,JAGSNPHARM.NS
Basic Average Shares,2024-03-31 00:00:00,66067647.0,JAGSNPHARM.NS
Diluted EPS,2024-03-31 00:00:00,3.39,JAGSNPHARM.NS
Basic EPS,2024-03-31 00:00:00,3.4,JAGSNPHARM.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Net Income Common Stockholders,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,JAGSNPHARM.NS
Net Income,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Net Income Continuous Operations,2024-03-31 00:00:00,224630000.0,JAGSNPHARM.NS
Tax Provision,2024-03-31 00:00:00,74060000.0,JAGSNPHARM.NS
Pretax Income,2024-03-31 00:00:00,298690000.0,JAGSNPHARM.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,92790000.0,JAGSNPHARM.NS
Special Income Charges,2024-03-31 00:00:00,0.0,JAGSNPHARM.NS
Other Special Charges,2024-03-31 00:00:00,,JAGSNPHARM.NS
Write Off,2024-03-31 00:00:00,,JAGSNPHARM.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-8140000.0,JAGSNPHARM.NS
Total Other Finance Cost,2024-03-31 00:00:00,370000.0,JAGSNPHARM.NS
Interest Expense Non Operating,2024-03-31 00:00:00,8140000.0,JAGSNPHARM.NS
Interest Income Non Operating,2024-03-31 00:00:00,85920000.0,JAGSNPHARM.NS
Operating Income,2024-03-31 00:00:00,214040000.0,JAGSNPHARM.NS
Operating Expense,2024-03-31 00:00:00,1073210000.0,JAGSNPHARM.NS
Other Operating Expenses,2024-03-31 00:00:00,435670000.0,JAGSNPHARM.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,16630000.0,JAGSNPHARM.NS
Depreciation Income Statement,2024-03-31 00:00:00,16630000.0,JAGSNPHARM.NS
Selling General And Administration,2024-03-31 00:00:00,201410000.0,JAGSNPHARM.NS
Selling And Marketing Expense,2024-03-31 00:00:00,163360000.0,JAGSNPHARM.NS
General And Administrative Expense,2024-03-31 00:00:00,38050000.0,JAGSNPHARM.NS
Rent And Landing Fees,2024-03-31 00:00:00,9130000.0,JAGSNPHARM.NS
Gross Profit,2024-03-31 00:00:00,1287250000.0,JAGSNPHARM.NS
Cost Of Revenue,2024-03-31 00:00:00,799770000.0,JAGSNPHARM.NS
Total Revenue,2024-03-31 00:00:00,2087020000.0,JAGSNPHARM.NS
Operating Revenue,2024-03-31 00:00:00,2087020000.0,JAGSNPHARM.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-6928129.74029,JAGSNPHARM.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.232332,JAGSNPHARM.NS
Normalized EBITDA,2023-03-31 00:00:00,392130000.0,JAGSNPHARM.NS
Total Unusual Items,2023-03-31 00:00:00,-29520000.0,JAGSNPHARM.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-29820000.0,JAGSNPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,267210000.0,JAGSNPHARM.NS
Reconciled Depreciation,2023-03-31 00:00:00,11750000.0,JAGSNPHARM.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,925140000.0,JAGSNPHARM.NS
EBITDA,2023-03-31 00:00:00,362610000.0,JAGSNPHARM.NS
EBIT,2023-03-31 00:00:00,350860000.0,JAGSNPHARM.NS
Net Interest Income,2023-03-31 00:00:00,30150000.0,JAGSNPHARM.NS
Interest Expense,2023-03-31 00:00:00,2780000.0,JAGSNPHARM.NS
Interest Income,2023-03-31 00:00:00,34280000.0,JAGSNPHARM.NS
Normalized Income,2023-03-31 00:00:00,290401870.25971,JAGSNPHARM.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,267210000.0,JAGSNPHARM.NS
Total Expenses,2023-03-31 00:00:00,2023840000.0,JAGSNPHARM.NS
Rent Expense Supplemental,2023-03-31 00:00:00,18310000.0,JAGSNPHARM.NS
Diluted Average Shares,2023-03-31 00:00:00,65495000.0,JAGSNPHARM.NS
Basic Average Shares,2023-03-31 00:00:00,65495000.0,JAGSNPHARM.NS
Diluted EPS,2023-03-31 00:00:00,4.08,JAGSNPHARM.NS
Basic EPS,2023-03-31 00:00:00,4.08,JAGSNPHARM.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,267210000.0,JAGSNPHARM.NS
Net Income Common Stockholders,2023-03-31 00:00:00,267210000.0,JAGSNPHARM.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,JAGSNPHARM.NS
Net Income,2023-03-31 00:00:00,267210000.0,JAGSNPHARM.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,267210000.0,JAGSNPHARM.NS
Net Income Continuous Operations,2023-03-31 00:00:00,267210000.0,JAGSNPHARM.NS
Tax Provision,2023-03-31 00:00:00,80870000.0,JAGSNPHARM.NS
Pretax Income,2023-03-31 00:00:00,348080000.0,JAGSNPHARM.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,4460000.0,JAGSNPHARM.NS
Special Income Charges,2023-03-31 00:00:00,-31300000.0,JAGSNPHARM.NS
Other Special Charges,2023-03-31 00:00:00,31000000.0,JAGSNPHARM.NS
Write Off,2023-03-31 00:00:00,2620000.0,JAGSNPHARM.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,30150000.0,JAGSNPHARM.NS
Total Other Finance Cost,2023-03-31 00:00:00,1350000.0,JAGSNPHARM.NS
Interest Expense Non Operating,2023-03-31 00:00:00,2780000.0,JAGSNPHARM.NS
Interest Income Non Operating,2023-03-31 00:00:00,34280000.0,JAGSNPHARM.NS
Operating Income,2023-03-31 00:00:00,343300000.0,JAGSNPHARM.NS
Operating Expense,2023-03-31 00:00:00,1098700000.0,JAGSNPHARM.NS
Other Operating Expenses,2023-03-31 00:00:00,185640000.0,JAGSNPHARM.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,11750000.0,JAGSNPHARM.NS
Depreciation Income Statement,2023-03-31 00:00:00,11750000.0,JAGSNPHARM.NS
Selling General And Administration,2023-03-31 00:00:00,234660000.0,JAGSNPHARM.NS
Selling And Marketing Expense,2023-03-31 00:00:00,178730000.0,JAGSNPHARM.NS
General And Administrative Expense,2023-03-31 00:00:00,55930000.0,JAGSNPHARM.NS
Rent And Landing Fees,2023-03-31 00:00:00,18310000.0,JAGSNPHARM.NS
Gross Profit,2023-03-31 00:00:00,1442000000.0,JAGSNPHARM.NS
Cost Of Revenue,2023-03-31 00:00:00,925140000.0,JAGSNPHARM.NS
Total Revenue,2023-03-31 00:00:00,2367140000.0,JAGSNPHARM.NS
Operating Revenue,2023-03-31 00:00:00,2367140000.0,JAGSNPHARM.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,-1382497.93559,JAGSNPHARM.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.292283,JAGSNPHARM.NS
Normalized EBITDA,2022-03-31 00:00:00,289020000.0,JAGSNPHARM.NS
Total Unusual Items,2022-03-31 00:00:00,-4730000.0,JAGSNPHARM.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,-4730000.0,JAGSNPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,188550000.0,JAGSNPHARM.NS
Reconciled Depreciation,2022-03-31 00:00:00,15260000.0,JAGSNPHARM.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,892820000.0,JAGSNPHARM.NS
EBITDA,2022-03-31 00:00:00,284290000.0,JAGSNPHARM.NS
EBIT,2022-03-31 00:00:00,269030000.0,JAGSNPHARM.NS
Net Interest Income,2022-03-31 00:00:00,12610000.0,JAGSNPHARM.NS
Interest Expense,2022-03-31 00:00:00,2610000.0,JAGSNPHARM.NS
Interest Income,2022-03-31 00:00:00,15460000.0,JAGSNPHARM.NS
Normalized Income,2022-03-31 00:00:00,191897502.06441,JAGSNPHARM.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,188550000.0,JAGSNPHARM.NS
Total Expenses,2022-03-31 00:00:00,1930390000.0,JAGSNPHARM.NS
Rent Expense Supplemental,2022-03-31 00:00:00,24770000.0,JAGSNPHARM.NS
Diluted Average Shares,2022-03-31 00:00:00,65495000.0,JAGSNPHARM.NS
Basic Average Shares,2022-03-31 00:00:00,65495000.0,JAGSNPHARM.NS
Diluted EPS,2022-03-31 00:00:00,2.88,JAGSNPHARM.NS
Basic EPS,2022-03-31 00:00:00,2.88,JAGSNPHARM.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,188550000.0,JAGSNPHARM.NS
Net Income Common Stockholders,2022-03-31 00:00:00,188550000.0,JAGSNPHARM.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,JAGSNPHARM.NS
Net Income,2022-03-31 00:00:00,188550000.0,JAGSNPHARM.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,188550000.0,JAGSNPHARM.NS
Net Income Continuous Operations,2022-03-31 00:00:00,188550000.0,JAGSNPHARM.NS
Tax Provision,2022-03-31 00:00:00,77870000.0,JAGSNPHARM.NS
Pretax Income,2022-03-31 00:00:00,266420000.0,JAGSNPHARM.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,1740000.0,JAGSNPHARM.NS
Special Income Charges,2022-03-31 00:00:00,430000.0,JAGSNPHARM.NS
Other Special Charges,2022-03-31 00:00:00,-850000.0,JAGSNPHARM.NS
Write Off,2022-03-31 00:00:00,420000.0,JAGSNPHARM.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,12610000.0,JAGSNPHARM.NS
Total Other Finance Cost,2022-03-31 00:00:00,240000.0,JAGSNPHARM.NS
Interest Expense Non Operating,2022-03-31 00:00:00,2610000.0,JAGSNPHARM.NS
Interest Income Non Operating,2022-03-31 00:00:00,15460000.0,JAGSNPHARM.NS
Operating Income,2022-03-31 00:00:00,245450000.0,JAGSNPHARM.NS
Operating Expense,2022-03-31 00:00:00,1037570000.0,JAGSNPHARM.NS
Other Operating Expenses,2022-03-31 00:00:00,180270000.0,JAGSNPHARM.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,15260000.0,JAGSNPHARM.NS
Depreciation Income Statement,2022-03-31 00:00:00,15260000.0,JAGSNPHARM.NS
Selling General And Administration,2022-03-31 00:00:00,240520000.0,JAGSNPHARM.NS
Selling And Marketing Expense,2022-03-31 00:00:00,138790000.0,JAGSNPHARM.NS
General And Administrative Expense,2022-03-31 00:00:00,101730000.0,JAGSNPHARM.NS
Rent And Landing Fees,2022-03-31 00:00:00,24770000.0,JAGSNPHARM.NS
Gross Profit,2022-03-31 00:00:00,1283020000.0,JAGSNPHARM.NS
Cost Of Revenue,2022-03-31 00:00:00,892820000.0,JAGSNPHARM.NS
Total Revenue,2022-03-31 00:00:00,2175840000.0,JAGSNPHARM.NS
Operating Revenue,2022-03-31 00:00:00,2175840000.0,JAGSNPHARM.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,JAGSNPHARM.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,JAGSNPHARM.NS
Normalized EBITDA,2021-03-31 00:00:00,,JAGSNPHARM.NS
Total Unusual Items,2021-03-31 00:00:00,,JAGSNPHARM.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,JAGSNPHARM.NS
Reconciled Depreciation,2021-03-31 00:00:00,,JAGSNPHARM.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,JAGSNPHARM.NS
EBITDA,2021-03-31 00:00:00,,JAGSNPHARM.NS
EBIT,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Interest Income,2021-03-31 00:00:00,,JAGSNPHARM.NS
Interest Expense,2021-03-31 00:00:00,,JAGSNPHARM.NS
Interest Income,2021-03-31 00:00:00,29924000.0,JAGSNPHARM.NS
Normalized Income,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,JAGSNPHARM.NS
Total Expenses,2021-03-31 00:00:00,,JAGSNPHARM.NS
Rent Expense Supplemental,2021-03-31 00:00:00,22687000.0,JAGSNPHARM.NS
Diluted Average Shares,2021-03-31 00:00:00,65495000.0,JAGSNPHARM.NS
Basic Average Shares,2021-03-31 00:00:00,65495000.0,JAGSNPHARM.NS
Diluted EPS,2021-03-31 00:00:00,2.604,JAGSNPHARM.NS
Basic EPS,2021-03-31 00:00:00,2.604,JAGSNPHARM.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,JAGSNPHARM.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Income,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,JAGSNPHARM.NS
Tax Provision,2021-03-31 00:00:00,,JAGSNPHARM.NS
Pretax Income,2021-03-31 00:00:00,,JAGSNPHARM.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,JAGSNPHARM.NS
Special Income Charges,2021-03-31 00:00:00,,JAGSNPHARM.NS
Other Special Charges,2021-03-31 00:00:00,,JAGSNPHARM.NS
Write Off,2021-03-31 00:00:00,,JAGSNPHARM.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,JAGSNPHARM.NS
Total Other Finance Cost,2021-03-31 00:00:00,860000.0,JAGSNPHARM.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,JAGSNPHARM.NS
Interest Income Non Operating,2021-03-31 00:00:00,29924000.0,JAGSNPHARM.NS
Operating Income,2021-03-31 00:00:00,,JAGSNPHARM.NS
Operating Expense,2021-03-31 00:00:00,,JAGSNPHARM.NS
Other Operating Expenses,2021-03-31 00:00:00,,JAGSNPHARM.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,JAGSNPHARM.NS
Depreciation Income Statement,2021-03-31 00:00:00,,JAGSNPHARM.NS
Selling General And Administration,2021-03-31 00:00:00,172624000.0,JAGSNPHARM.NS
Selling And Marketing Expense,2021-03-31 00:00:00,129901000.0,JAGSNPHARM.NS
General And Administrative Expense,2021-03-31 00:00:00,42723000.0,JAGSNPHARM.NS
Rent And Landing Fees,2021-03-31 00:00:00,22687000.0,JAGSNPHARM.NS
Gross Profit,2021-03-31 00:00:00,,JAGSNPHARM.NS
Cost Of Revenue,2021-03-31 00:00:00,,JAGSNPHARM.NS
Total Revenue,2021-03-31 00:00:00,,JAGSNPHARM.NS
Operating Revenue,2021-03-31 00:00:00,,JAGSNPHARM.NS
